德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06996 德琪医药-B

已收盘 09-01 16:08:13

3.550

-0.125

-3.40%

最高3.830	最低3.525	成交量107.25万
今开3.830	昨收3.675	日振幅8.30%
总市值24.03亿	流通市值24.03亿	总股本6.77亿
成交额381.93万	换手率0.16%	流通股本6.77亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06996","market":"HK","secType":"STK","nameCN":"德琪医药-B","latestPrice":3.55,"timestamp":1788250093007,"preClose":3.675,"halted":0,"volume":1072500,"delay":0,"changeRate":-0.034013605442176874,"floatShares":677000000,"shares":677000000,"eps":-0.4430805780102086,"marketStatus":"已收盘","change":-0.125,"latestTime":"09-01 16:08:13","open":3.83,"high":3.83,"low":3.525,"amount":3819290,"amplitude":0.082993,"askPrice":3.55,"askSize":500,"bidPrice":3.53,"bidSize":46500,"shortable":3,"etf":0,"ttmEps":0.09806189392430671,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788312600000},"marketStatusCode":5,"adr":0,"listingDate":1605801600000,"exchange":"SEHK","adjPreClose":3.675,"openAndCloseTimeList":[[1788226200000,1788235200000],[1788238800000,1788249600000]],"volumeRatio":0.628222,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06996","defaultTab":"news","newsList":[{"id":"1128345154","title":"德琪医药ATG-201（CD19 x CD3 TCE）B细胞相关自身免疫疾病I期ATTRACT研究获澳大利亚临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1128345154","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1128345154?lang=zh_cn&edition=full","pubTime":"2026-08-25 08:31","pubTimestamp":1787617871,"startTime":"0","endTime":"0","summary":"德琪医药宣布，其在澳大利亚开展的ATG-201用于治疗B细胞相关自身免疫疾病的I期ATTRACT研究，已正式获得临床试验批准。ATG-201的设计初衷在于精准靶向并清除致病性B细胞，从而有望为系统性红斑狼疮、类风湿性关节炎等一系列B细胞驱动的自身免疫疾病患者带来全新的治疗选择。公司计划尽快启动患者招募，并期待ATG-201能够释放潜力，改写自身免疫疾病的治疗格局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996","BK1191","BK1583","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662201084","title":"德琪医药-B(06996)：ATG-201用于治疗由B细胞介导的自身免疫性疾病的I期ATTRACT研究在澳大利亚获HREC批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2662201084","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662201084?lang=zh_cn&edition=full","pubTime":"2026-08-25 07:00","pubTimestamp":1787612436,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B(06996)发布公告，本公司董事会欣然宣布，集团自主研发的ATG-201(一种用于治疗B细胞相关自身免疫性疾病的CD19/CD3双特异性T细胞衔接抗体)的I期ATTRACT研究，已获得澳大利亚人类研究伦理委员会(HREC)批准，并已完成向治疗用品管理局(TGA)提交临床试验通知(CTN)的程序。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484743.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06996","BK1191","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160770393","title":"德琪医药-B（06996）自主研发ATG-201澳大利亚I期临床获HREC批准并完成TGA CTN提交","url":"https://stock-news.laohu8.com/highlight/detail?id=1160770393","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160770393?lang=zh_cn&edition=full","pubTime":"2026-08-25 06:45","pubTimestamp":1787611530,"startTime":"0","endTime":"0","summary":"德琪医药有限公司－德琪医药-B（06996）8月25日自愿公告称，其自主研发的CD19/CD3双特异性T细胞衔接抗体ATG-201用于治疗B细胞相关自身免疫性疾病的I期ATTRACT研究，已获澳大利亚人类研究伦理委员会（HREC）批准，并已完成向澳大利亚治疗用品管理局（TGA）提交临床试验通知（CTN）的程序。\n公告提示，ATG-201最终可能无法成功开发及商业化，公司提醒股东及潜在投资者在买卖公司证券时保持审慎。\n截至公告日，公司董事会由执行董事梅建明博士、侯冰博士，以及独立非执行董事钱晶女士、唐晟先生及Rafael Fonseca博士组成。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661262311","title":"德琪医药-B(06996)发布中期业绩 净利润2.16亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2661262311","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661262311?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:44","pubTimestamp":1787309051,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B 发布截至2026年6月30日止六个月中期业绩公告，集团收入5.13亿元，同比增长864.75%;净利润2.16亿元，同比扭亏为盈;每股盈利0.34元。作为回报，德琪获得6000万美元的首付款，且在满足若干条件后将获得额外2000万美元的近期里程碑付款，并有资格获得最高约11亿美元基于开发及商业化成功的未来里程碑付款，以及按未来净销售额计算的分级特许权使用费。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483443.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B(06996)发布中期业绩 净利润2.16亿元 同比扭亏为盈","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196932549","title":"德琪医药-B（06996）上半年扭亏为盈，授权合作收入大增推动营收至5.13亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1196932549","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1196932549?lang=zh_cn&edition=full","pubTime":"2026-08-21 18:31","pubTimestamp":1787308295,"startTime":"0","endTime":"0","summary":"2026年8月21日，德琪医药-B发布截至2026年6月30日止六个月未经审计中期业绩。收入大幅增长：报告期内，集团实现收入人民币5.13亿元，较2025年同期的0.53亿元增加人民币4.60亿元。该增长主要源于确认授权及合作收入4.58亿元，其中包括针对ATG-201与UCB及ATG-106与K2 Therapeutics两项对外授权安排的前期对价457.86百万元。经调整后期内利润为人民币2.17亿元；若进一步扣除汇兑差额净额后，经调整利润为人民币2.85亿元，而上年同期为亏损0.85亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658950339","title":"德琪医药-B(06996.HK)拟8月21日举行董事会会议以批准中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2658950339","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658950339?lang=zh_cn&edition=full","pubTime":"2026-08-11 06:57","pubTimestamp":1786402622,"startTime":"0","endTime":"0","summary":"格隆汇8月11日丨德琪医药-B(06996.HK)宣布，公司将于2026年8月21日(星期五)举行董事会会议，藉以(其中包括)考虑并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩及其发布。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260811/32330933.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["06996","BK1191","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158733868","title":"德琪医药有限公司（06996）将于2026年8月21日审议中期业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1158733868","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158733868?lang=zh_cn&edition=full","pubTime":"2026-08-11 06:10","pubTimestamp":1786399835,"startTime":"0","endTime":"0","summary":"德琪医药有限公司（06996）今日公告称，公司董事会已排期于2026年8月21日（星期五）召开会议，届时将审议并批准公司及其附属公司截至2026年6月30日止六个月的中期业绩，并讨论业绩公告的发布事宜。公告显示，董事会目前由执行董事梅建明博士和侯冰博士；独立非执行董事钱晶女士、唐晟先生及Rafael Fonseca博士组成。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115044930","title":"德琪医药-B更新2026年7月股份变动月报表，股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1115044930","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115044930?lang=zh_cn&edition=full","pubTime":"2026-08-05 18:42","pubTimestamp":1785926526,"startTime":"0","endTime":"0","summary":"德琪医药有限公司于2026年8月5日发布2026年7月股份变动月报表，报告期截至2026年7月31日。公告显示，公司本月未发生新增发行行为，整体股本维持在679,446,632股不变，法定/注册股本亦维持在2,000,000,000股。根据月报，德琪医药-B的已发行股份于月初为679,244,132股，报告期内减少1,826,500股至677,417,632股，同时对应库存股数量由202,500股增加至2,029,000股。截至2026年7月底，公司总股本为679,446,632股，未发生注销，持股总数保持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156125130","title":"德琪医药-B（06996）公布最新董事会名单及委员会组成","url":"https://stock-news.laohu8.com/highlight/detail?id=1156125130","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1156125130?lang=zh_cn&edition=full","pubTime":"2026-08-03 08:06","pubTimestamp":1785715578,"startTime":"0","endTime":"0","summary":"2026年8月1日，德琪医药-B发布公告，披露公司董事会及各专门委员会成员最新组成情况。董事会下设四个专门委员会：审计委员会、薪酬委员会、提名及企业管治委员会以及科学委员会。各董事在相关委员会的职务分配如下：。提名及企业管治委员会：主席为 Rafael Fonseca博士；梅建明博士及钱晶女士担任成员。上述安排自公告日起生效。公司表示，新的董事会及其专门委员会架构旨在进一步完善公司治理机制，确保董事会决策的专业性与独立性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112861631","title":"德琪医药-B（06996）宣布管理层调整：首席财务官辞任、任命新执行董事及首席商务官","url":"https://stock-news.laohu8.com/highlight/detail?id=1112861631","media":"公告速递","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1112861631?lang=zh_cn&edition=full","pubTime":"2026-07-31 17:01","pubTimestamp":1785488510,"startTime":"0","endTime":"0","summary":"德琪医药-B7月31日晚间发布公告称，公司董事会收到龙振国先生的辞呈。因寻求其他职业发展机会，龙振国将于2026年8月1日辞去执行董事及首席财务官职务，并同时卸任上市规则第3.05条所规定的公司授权代表及香港《公司条例》第16部和上市规则第19.05条所规定的法律程序文件代理人。龙振国确认，其与董事会并无分歧，亦无其他须提请股东或香港联交所关注的事项。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655235948","title":"德琪医药-B(06996)：侯冰获委任为执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2655235948","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655235948?lang=zh_cn&edition=full","pubTime":"2026-07-31 16:57","pubTimestamp":1785488230,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B 发布公告，龙振国先生为寻求其他职业发展机会，已提出辞任本公司执行董事及首席财务官的职务，自2026年8月1日生效。侯冰博士已获委任为执行董事，自2026年8月1日起生效。郭睿女士已获委任为本公司首席商务官，自2026年8月1日起生效。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1474623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B(06996)：侯冰获委任为执行董事","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06996","BK1191","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654458022","title":"【券商聚焦】交银国际：下半年医药板块有望迎来修复 但内部分化或持续加大","url":"https://stock-news.laohu8.com/highlight/detail?id=2654458022","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654458022?lang=zh_cn&edition=full","pubTime":"2026-07-28 10:01","pubTimestamp":1785204072,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，近一个月恒生医疗保健指数涨17.4%，跑赢大市。其中，生物药、CXO及处方药板块表现较优于其他板块。机构持仓方面，2026年年中以来，内资持仓延续提升态势，而外资则略有降低。该机构指，中报季临近，7月以来多家公司业绩预告陆续发布，CXO板块表现亮眼，业绩和订单延续高增长态势。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986903","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02162","00013","LU1880383366.USD","09996","KURE","03759","01548","LU2328871848.SGD","01093","01801","06078","LU0417516571.SGD","LU2097828714.EUR","03329","02268","LU2039709279.SGD","02269","01276","01177","LU0856984785.SGD","09939","02273","KCE","06160","BK1521","06990","09926","LU0634319403.HKD","06821","LU2476274308.USD","LU1813983027.USD","159938","02096","02596","03692","LU0572944931.SGD","BK1587","HK0000320223.HKD","01951","LU0348783233.USD","LU2399975544.HKD","09966","LU1720050803.USD","01952","06996","LU0588546209.SGD","LU0196878994.USD","01530","HK0000165453.HKD","BK1219"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654266430","title":"德琪医药-B(06996)发盈喜 预计上半年利润约1.95亿元至2.38亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2654266430","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654266430?lang=zh_cn&edition=full","pubTime":"2026-07-28 06:33","pubTimestamp":1785191602,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B 发布公告，集团预期将于截至2026年6月30日止六个月取得收入介于人民币4.90亿元至5.36亿元，而于截至2025年6月30日止六个月则取得收入约人民币5320万元;于本期间取得利润介于人民币1.95亿元至2.38亿元，而于相应期间则取得亏损约人民币7640万元。本期间收入预期增加及由亏转盈主要由于：自2026年3月起生效、与优时比就ATG-201 订立的对外授权及合作安排，为本期间的主要收入动力。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1472862.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B(06996)发盈喜 预计上半年利润约1.95亿元至2.38亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1583","06996","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654026648","title":"德琪医药-B(06996.HK)发盈喜 预计上半年利润约1.95亿元至2.38亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2654026648","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654026648?lang=zh_cn&edition=full","pubTime":"2026-07-28 06:33","pubTimestamp":1785191602,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","BK1574","06996","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108264055","title":"德琪医药-B（06996）发布正面盈利预告：上半年营收预计4.90亿至5.36亿元，转亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=1108264055","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1108264055?lang=zh_cn&edition=full","pubTime":"2026-07-28 06:25","pubTimestamp":1785191141,"startTime":"0","endTime":"0","summary":"德琪医药-B7月28日在港交所公告称，根据对截至2026年6月30日止六个月未 audited 综合管理账目的初步审阅，预计实现以下业绩：\\n\\n 收入预计介于人民币4.90亿元至5.36亿元，较截至2025年6月30日止六个月约人民币53.2百万元显著增加。\\n\\n 归属于股东的利润预计介于人民币1.95亿元至2.38亿元，而相应期间录得亏损约人民币76.4百万元，实现由亏转盈。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162016502","title":"德琪医药-B回购24.45万股股份，合共耗资约100.40万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1162016502","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162016502?lang=zh_cn&edition=full","pubTime":"2026-07-21 17:35","pubTimestamp":1784626551,"startTime":"0","endTime":"0","summary":"德琪医药-B于2026年7月21日发布翌日披露报表，公告显示，公司于当日于香港联交所回购普通股24.45万股，约占此前已发行股本6.7766亿股的0.0361%。本次回购每股价格介乎港币3.95元至4.24元，合共耗资约100.40万港元。本次变动后，公司于2026年7月21日的已发行股本总数维持为6.7945亿股，其中6.7742亿股为已发行股份，202.90万股为库存股份。公司确认本次回购操作已遵守香港联交所相关上市规则及当地适用法规。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B回购24.45万股股份，合共耗资约100.40万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185829185","title":"德琪医药-B：7月20日回购24.3万股股份，耗资约100.30万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1185829185","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185829185?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:02","pubTimestamp":1784541768,"startTime":"0","endTime":"0","summary":"德琪医药有限公司于2026年7月20日发布公告，披露当日在香港联交所回购普通股243,000股，占该次回购前公司已发行股份总数的0.0358%。回购价格介乎每股港币4.07元至4.20元，累计支付总金额合计约港币100.30万。回购完成后，公司已发行股本为677,662,132股，库存股份增加至1,784,500股，总股本仍维持在679,446,632股。公告显示，此次回购基于2026年6月10日通过的购回授权，该授权可供回购的股份总数为67,924,413股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B：7月20日回购24.3万股股份，耗资约100.30万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652423294","title":"德琪医药-B(06996)7月20日斥资100.3万港元回购24.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652423294","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652423294?lang=zh_cn&edition=full","pubTime":"2026-07-20 18:01","pubTimestamp":1784541677,"startTime":"0","endTime":"0","summary":"智通财经APP讯，德琪医药-B(06996)发布公告，该公司于2026年7月20日斥资100.3万港元回购24.3万股股份，每股回购价格为4.07-4.2港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","06996","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176825644","title":"德琪医药-B回购499,000股股份，耗资约200.34万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1176825644","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1176825644?lang=zh_cn&edition=full","pubTime":"2026-07-17 18:00","pubTimestamp":1784282455,"startTime":"0","endTime":"0","summary":"德琪医药有限公司于2026年7月17日发布公告，披露该公司于香港联交所场内回购499,000股普通股，占本次回购前公司已发行股份总数约0.0736%。回购价格介乎每股3.86港元至4.15港元之间，合计使用资金约200.34万港元。公告显示，本次回购完成后，公司已发行股份数量为677,905,132股，库藏股数为1,541,500股，合计股份总数为679,446,632股。公司亦披露，于2026年6月10日获得的股份回购授权可再回购最高达67,924,413股，此前已合计回购1,339,000股。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B回购499,000股股份，耗资约200.34万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102919041","title":"德琪医药-B回购22.55万股股份，总额约100.39万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102919041","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1102919041?lang=zh_cn&edition=full","pubTime":"2026-07-16 18:11","pubTimestamp":1784196697,"startTime":"0","endTime":"0","summary":"2026年7月16日，德琪医药-B在香港联交所披露翌日披露报表，公司于当日通过场内交易回购普通股225,500股，占回购前公司已发行股本约0.0332%。回购价格在每股4.37港元至4.54港元之间，涉资合计约100.39万港元。公司购回授权于2026年6月10日通过，授权范围内尚可回购67,924,413股。此外，公司确认本次回购活动符合香港联合交易所有限公司证券上市规则及相关法律法规。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德琪医药-B回购22.55万股股份，总额约100.39万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06996"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.antengene.com","stockEarnings":[{"period":"1week","weight":-0.0553},{"period":"1month","weight":-0.0673},{"period":"3month","weight":-0.0528},{"period":"6month","weight":0.163},{"period":"1year","weight":-0.4231},{"period":"ytd","weight":-0.0303}],"compareEarnings":[{"period":"1week","weight":0.0019},{"period":"1month","weight":-0.0123},{"period":"3month","weight":-0.0181},{"period":"6month","weight":0.0126},{"period":"1year","weight":0.0195},{"period":"ytd","weight":-0.0025}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"德琪医药有限公司是一家专注于创新抗肿瘤药物的亚太地区临床阶段生物制药公司。该公司主要从事生物科技产品的发现、开发、生产及商业化。该公司的主要产品包括用于治疗复发╱难治性多发性骨髓瘤、复发╱难治性弥漫大B细胞淋巴瘤和非小细胞肺癌的ATG-010(selinexor)及用于治疗肝细胞癌和非小细胞肺癌等多种适应症的ATG-008(onatasertib)。该公司主要在亚太地区开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.088806},{"month":2,"riseRate":0.166667,"avgChangeRate":0.291534},{"month":3,"riseRate":0.5,"avgChangeRate":0.091928},{"month":4,"riseRate":0.5,"avgChangeRate":-0.034689},{"month":5,"riseRate":0.5,"avgChangeRate":0.014763},{"month":6,"riseRate":0.166667,"avgChangeRate":-0.127204},{"month":7,"riseRate":0.333333,"avgChangeRate":0.018605},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.036567},{"month":9,"riseRate":0.4,"avgChangeRate":-0.020432},{"month":10,"riseRate":0.4,"avgChangeRate":0.032822},{"month":11,"riseRate":0.6,"avgChangeRate":0.05603},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.002542}],"exchange":"SEHK","name":"德琪医药-B","nameEN":"ANTENGENE-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供德琪医药-B(06996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"德琪医药-B,06996,德琪医药-B股票,德琪医药-B股票老虎,德琪医药-B股票老虎国际,德琪医药-B行情,德琪医药-B股票行情,德琪医药-B股价,德琪医药-B股市,德琪医药-B股票价格,德琪医药-B股票交易,德琪医药-B股票购买,德琪医药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"德琪医药-B(06996)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供德琪医药-B(06996)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}